On the Record · Novartis
Novartis competitors, on the record
The companies whose own annual reports name Novartis as a competitor, each with the sentence it appears in and the filing it came from.
Who Novartis names
Novartis’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Novartis
Companies whose own annual reports name Novartis as a competitor.
Word for word“Product Territory Competitor-marketed product Competitors Prolia U.S., Europe & Asia Pacific Bisphosphonates, including generics Various U.S., Europe & Asia Pacific Denosumab biosimilars Various Repatha U.S., Europe & Asia Pacific LEQVIO ® Novartis AG U.S., Europe & Asia Pacific PRALUENT ® Regeneron Pharmaceuticals, Inc.” 10-K for 2025
Word for word“Furthermore, in December 2023, the FDA approved iptacopan (marketed as Fabhalta), an orally administered factor B inhibitor developed by Novartis, for the treatment of PNH.” 10-K for 2025
Word for word“Zolgensma (Onasemnogene abeparvovec) Novartis Gene therapy targeting the genetic root cause of SMA by replacing the missing or nonworking SMN1 gene Approved for pediatric SMA patients less than 2 years of age Intravenous Infusion” 10-K for 2025
Word for word“In other specialties and biosimilar products, we compete with products produced by some of the largest pharmaceutical manufacturers in the world, such as Novartis AG, AstraZeneca AB, Sanofi and GlaxoSmithKline.” 20-F for 2025
Word for word“For LNTH-2501, our principal competitors may include Curium and Novartis AG.” 10-K for 2025
Word for word“Novartis' Kymriah is approved for the treatment of children and young adults with ALL that is refractory or has relapsed at least twice and for adults with relapsed or refractory diffuse large B cell lymphoma ("DLBCL").” 20-F for 2025
Word for word“Novartis is also developing OAV-101, an intrathecal administration of Zolgensma, for SMA patients ages ≥ 2 to < 18 years of age.” 10-K for 2025
Read from Novartis’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-04. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.